New evidence reveals that the expensive Nicotine Replacement Therapy products marketed by big pharm are effective for a tiny 1.6% of smokers.
Measured over a 12 month period 98.4% of smokers were unable to quit with the NRT products.
These finds have been exposed in a post by Michael Sigael, a professor in the Boston University School of Public Health.
Given that:
the implications of denying e-smokers the choice to safer alternatives is clear.
1. Profits for big pharm who can continue to sell expensive products that don’t work.
2. Safeguarding the estabished tobacco industry.
And for at least a third of e-smokers?
Death.
Like this post? Keep up to date with us by signing up for our email updates.
No related posts.
Leave a comment:
